A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.
Hongjie QianQian ChenLiyu LiangYang ZouHuahua PuLiang XinRong SongTingting LiHuijuan ZhuYu WangGuanghui TianJingshan ShenHualiang JiangChen YuZhen WangJingying JiaPublished in: Drug design, development and therapy (2021)
TPN171H was safe and generally tolerated in healthy subjects. Based on the half-life, food effect, and safety profile of TPN171H, we recommend a once-daily, post-meal administration of TPN171H in subsequent clinical studies in healthy subjects and patients with PAH.